Results 61 to 70 of about 22,516 (228)
Journal of Clinical Laboratory Analysis, EarlyView.This study evaluates the association between Notch1 and Notch3 genetic variations and serum protein levels in patients with benign prostatic hyperplasia and prostate cancer. While genetic variations showed no significant link to disease risk, serum protein levels were significantly lower in prostate cancer and metastatic groups compared to healthy ...
Emine Yagci +4 more
wiley +1 more source
Human CRPC tissue microarray (TMA) analysis.
, 2019 TMA was obtained from the rapid autopsy program at the University of Michigan. This array contains 51 CRPC samples as well as 16 benign prostate tissues and 12 localized prostate cancer tissues for controls. A.
Ganesh Palapattu (1849828) +7 more
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan +4 more
wiley +1 more source
Systematically understanding the immunity leading to CRPC progression
, 2019 Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has become a standard treatment strategy for advanced PCa.
Hui-Kuan Lin +7 more
core +1 more source
Forest plot odds ratio (OR) of Skeletal related events (SREs) in subgroup of HSPC and CRPC.
, 2022 Forest plot odds ratio (OR) of Skeletal related events (SREs) in subgroup of HSPC and CRPC.
Mandi Lin (13844322) +8 more
core +1 more source
Clinical and Translational Medicine, 2021 Castration‐resistant prostate cancer (CRPC) is the latest stage of PCa, and there is almost no effective treatment available for the patients with CRPC when next‐generation androgen deprivation therapy drugs, such as enzalutamide (ENZ), fail.
Zhe Hong +8 more
doaj +1 more source
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Mass Spectrometry Reviews, EarlyView.Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source
MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
, 2016 186 Background: The mixed-lineage leukemia (MLL) protein is a histone methyltransferase that regulates multiple genetic elements. Chromosomal rearrangements of the MLL gene result in expression of MLL-fusion proteins that occur in a subset of acute ...
Elisa M. Ledet +3 more
core +1 more source
Adrenal stimulation of CRPC growth in an in vitro co-culture model.
Introduction: In the majority of castration resistant prostate cancers (CRPC), the AR is still active despite low serum testosterone levels. Among other mechanisms of AR-activation, intratumoral androgen synthesis, either via conversion of adrenal ...
Hickson I +5 more
core +4 more sources
The Prostate, EarlyView.ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento +15 more
wiley +1 more source